3 Biotechnology Stocks With Promising Pipelines

As the biotechnology sector continues to thrive amidst increasing drug discovery rates and a surge in research and development initiatives, now could be an ideal time for investors to consider positioning themselves in fundamentally strong biotech stocks. Many companies in the industry are expected to benefit from the Federal Reserve’s recent interest rate cuts, which have lowered borrowing costs and are anticipated to lead to increased investment and improved market sentiment. Advancements in technology are also accelerating the sector’s growth, with the global biotechnology market projected to reach $4.61 trillion by 2034, growing at a compound annual growth rate (CAGR) of 11.5%. Here, we will examine three notable biotech stocks: Amgen Inc. (AMGN), Regeneron Pharmaceuticals, Inc. (REGN), and Gilead Sciences, Inc. (GILD), which boast promising pipelines.

The Growing Biotech Landscape

The biotechnology industry is gaining momentum due to a rising tide of chronic diseases, the growing demand for personalized medicine, and the rapid evolution of drug discovery processes driven by cutting-edge technologies, including Artificial Intelligence (AI). In 2024, the U.S. Food and Drug Administration (FDA) has approved over 38 new drugs targeting critical health issues such as schizophrenia, urinary tract infections, breast cancer, lung cancer, and Alzheimer’s disease. The robust R&D landscape is expected to accelerate breakthroughs in the sector.

Stock #3: Amgen Inc. (AMGN)

Amgen Inc. is a global leader in discovering, developing, manufacturing, and delivering human therapeutics. The company’s product portfolio features major drugs such as Enbrel, Otezla, and Repatha. Recent developments include the FDA approval of Otezla for pediatric use, making it the first approved oral treatment for children aged 6-17 with moderate to severe plaque psoriasis. Additionally, AMGN’s BLINCYTO received authorization for treating patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

In the third quarter ending September 30, 2024, Amgen reported total revenues of $8.50 billion, marking a 23.2% year-over-year increase. Their non-GAAP net income reached $3.02 billion, translating to an EPS of $5.58. Notably, AMGN’s shares surged 16.9% in the past six months and 25.2% over the last year, closing at $320.16. The company’s overall POWR Ratings indicate a solid performance, earning a “B” rating and ranking #25 out of 329 biotech stocks.

Stock #2: Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals is dedicated to discovering and commercializing medicines for diverse health conditions globally. Its key products include EYLEA, an injection for treating diabetic macular edema (DME), and Dupixent, approved as an add-on treatment for chronic obstructive pulmonary disease (COPD).

In the third quarter of 2024, Regeneron’s revenues increased to $3.72 billion, reflecting a 10.6% growth year-over-year. The company also reported non-GAAP EPS of $12.46. Currently, REGN shares have risen 7.5% over the past year, closing last session at $838.20. Its current POWR Ratings position REGN as a strong buy with an overall rating of “A” and ranking #9 in its industry.

Stock #1: Gilead Sciences, Inc. (GILD)

Gilead Sciences focuses on discovering, developing, and commercializing innovative medicines to meet unmet medical needs. The biopharmaceutical company’s portfolio includes several antiviral treatments, including Biktarvy and Descovy. Recently, Gilead expanded its partnership with AbTherx to enhance novel antibody discovery.

In the second quarter of 2024, Gilead’s revenues reached $6.95 billion, up 5.4% year-over-year. The company also surpassed consensus revenue estimates in all trailing four quarters. GILD’s stock has gained 36.2% in the past six months, closing at $88.82, and has an overall POWR Rating of “A,” indicating a strong buy with a robust outlook.

Conclusion

As the biotech industry prepares for significant growth driven by innovative drug discoveries and favorable economic conditions, investors might find opportunities in companies with promising pipelines like Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD). Each of these companies demonstrates solid fundamentals, making them potentially valuable additions to a diversified investment portfolio.

DISCLAIMERS – THIS IS A PAID ADVERTISEMENT.

TipsForTraders.com

This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.

This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

For a full disclaimer & disclosure please click here.

This communication is a paid advertisement and is not a recommendation to buy or sell securities. IR PUB Network, and its owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled companies or a third party to disseminate this communication. IThis compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication.

Gains mentioned in this article, in our newsletter and on our website may be based on end-of-day or intraday data. Therefore, this communication should be viewed as a commercial advertisement only. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IR PUB Network often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, and approved by the company that is featured herein, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s).

You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. We have not thoroughly investigated the background of any of the companies we profile. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on Companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.

Blog

Three Promising Biotechnology Stocks to Invest In Now